Business Context and Reporting Period
enGene Holdings Inc. filed this Form 8-K on December 28, 2023, reporting events occurring on December 22, 2023. The filing concerns an amended debt financing with Hercules Capital, Inc. and related warrant issuance. The registrant is a British Columbia corporation with common shares and warrants traded on Nasdaq under ENGN and ENGNW.
Material Financing Terms and Key Metrics
- Total facility: Up to $50.0 million in term loans available in multiple tranches.
- Initial borrowing: $22.5 million funded on December 22, 2023, including approximately $8.6 million used to refinance the prior Hercules term loans.
- Additional tranche: Up to $7.5 million may become available upon achievement of an Interim Milestone and satisfaction of other conditions, during the specified availability period ending no later than March 31, 2025.
- Uncommitted tranche: Up to $20.0 million may be requested through the Amortization Date, subject to lender investment committee approval and other conditions, including a 0.75% facility charge.
- Interest: Cash interest is payable monthly at the greater of the Wall Street Journal prime rate plus 0.75%, capped at 9.75%, or 9.25%. Additional payment-in-kind interest accrues at 1.15% annually and is added to principal monthly.
- Maturity: January 1, 2028, with no extension option.
- Amortization: Monthly interest-only payments continue until July 1, 2025, or potentially January 1, 2026 or July 1, 2026 if specified milestones are achieved and no default exists. Thereafter, principal and accrued interest are payable in equal monthly installments through maturity.
- Fees: A 5.50% end-of-term fee is due upon maturity or earlier repayment. A separate $698,500 charge under the prior loan agreement is due July 1, 2025 or earlier repayment.
- Prepayment: All outstanding term loans may be prepaid, subject to accrued amounts and a charge of 3.0% during the first year, 2.0% during the second year, or 1.0% thereafter before maturity.
Warrants, Security and Covenants
- The company issued 62,413 warrants to the lenders at closing. Each warrant has an exercise price of $7.21 per common share, is exercisable for seven years, and is subject to customary adjustments.
- Warrants issued in connection with each advance represent 2% of the related principal advance divided by the exercise price. Assuming the full $50.0 million commitment is drawn, up to 138,696 warrants could be issued, before adjustments.
- The borrowers granted Hercules a senior security interest in substantially all assets, subject to limited exceptions, including intellectual property.
- Negative covenants restrict, subject to exceptions, additional liens and indebtedness, investments and acquisitions, fundamental changes, asset dispositions, dividends and certain equity repurchases, amendments to material agreements, and payments of subordinated debt.
- The company stated that the borrowers had complied with financial and non-financial covenants since inception of the prior term loan.
- The warrants were issued in an unregistered transaction relying on Section 4(a)(2) of the Securities Act.
Outlook, Risks and Unusual Items
The filing does not provide revenue, profitability, cash flow, liquidity balances, operating guidance, or broader management outlook. Access to the additional $7.5 million tranche depends on achievement of an Interim Milestone and other conditions; access to the potential $20.0 million tranche is uncommitted and requires lender approval.
Key financial risks include high contractual interest costs, monthly capitalization of PIK interest, mandatory fees, prepayment charges, collateral priority in favor of Hercules, restrictive covenants, and the possibility that milestone-based or discretionary borrowing capacity will not become available. The filing does not state whether the Interim Milestone or later clinical milestones had been achieved as of the filing date.
Important Facts for Investors to Verify
- Whether the company draws any of the additional $7.5 million or $20.0 million tranches and satisfies the related milestones and conditions.
- The company’s cash balance, cash-burn rate, and ability to fund operations and debt service through the January 2028 maturity.
- The applicable cash interest rate over time and the impact of 1.15% PIK interest on outstanding principal.
- The effect of the senior security interest and restrictive covenants on financing flexibility and intellectual-property-related transactions.
- The number of warrants ultimately issued and potential dilution if the warrants are exercised.
- Any future defaults, covenant breaches, milestone failures, refinancing needs, or changes to the debt agreement.